Elcelyx Therapeutics has started enrolling type 2 diabetics for its dose finding, phase 2b clinical trial of its lead product NewMet. The company will be enrolling almost 240 patients in multiple centers across the United States.
http://bionews-tx.com/news/2013/05/21/elcelyx-therapeutics-enrolling-phase-2b-trial-for-its-type-2-diabetes-drug-newmet/
No comments:
Post a Comment